Annual Accounts Payable
$11.39 M
-$24.48 M-68.25%
September 30, 2024
Summary
- As of February 7, 2025, ARWR annual accounts payable is $11.39 million, with the most recent change of -$24.48 million (-68.25%) on September 30, 2024.
- During the last 3 years, ARWR annual accounts payable has risen by +$1.93 million (+20.42%).
- ARWR annual accounts payable is now -68.25% below its all-time high of $35.87 million, reached on September 30, 2023.
Performance
ARWR Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Accounts Payable
$11.39 M
-$15.16 M-57.11%
September 30, 2024
Summary
- As of February 7, 2025, ARWR quarterly accounts payable is $11.39 million, with the most recent change of -$15.16 million (-57.11%) on September 30, 2024.
- Over the past year, ARWR quarterly accounts payable has increased by +$2.87 million (+33.65%).
- ARWR quarterly accounts payable is now -68.25% below its all-time high of $35.87 million, reached on September 30, 2023.
Performance
ARWR Quarterly Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Accounts Payable Formula
Accounts Payable = Beginning Accounts Payable + Purchases on Credit − Payments to Suppliers
ARWR Accounts Payable Trends
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
---|---|---|
1 y1 year | -68.3% | +33.6% |
3 y3 years | +20.4% | +20.4% |
5 y5 years | +48.9% | +20.4% |
ARWR Accounts Payable Highs & Lows
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
---|---|---|---|---|---|
3 y | 3-year | -68.3% | +297.1% | -68.3% | +1330.7% |
5 y | 5-year | -68.3% | +297.1% | -68.3% | +1330.7% |
alltime | all time | -68.3% | >+9999.0% | -68.3% | >+9999.0% |
Arrowhead Pharmaceuticals Accounts Payable History
Date | Annual | Quarterly |
---|---|---|
Sep 2024 | $11.39 M(-68.2%) | $11.39 M(-57.1%) |
Jun 2024 | - | $26.55 M(+211.6%) |
Mar 2024 | - | $8.52 M(+91.1%) |
Dec 2023 | - | $4.46 M(-87.6%) |
Sep 2023 | $35.87 M(+1150.6%) | $35.87 M(+355.5%) |
Jun 2023 | - | $7.87 M(-17.6%) |
Mar 2023 | - | $9.56 M(+1100.5%) |
Dec 2022 | - | $796.00 K(-72.2%) |
Sep 2022 | $2.87 M(-69.7%) | $2.87 M(-51.3%) |
Jun 2022 | - | $5.89 M(-44.4%) |
Mar 2022 | - | $10.60 M(+160.6%) |
Dec 2021 | - | $4.07 M(-57.0%) |
Sep 2021 | $9.46 M(+38.5%) | $9.46 M(-5.8%) |
Jun 2021 | - | $10.04 M(+89.4%) |
Mar 2021 | - | $5.30 M(+9.8%) |
Dec 2020 | - | $4.83 M(-29.3%) |
Sep 2020 | $6.83 M(-10.7%) | $6.83 M(+67.6%) |
Jun 2020 | - | $4.07 M(-69.6%) |
Mar 2020 | - | $13.42 M(+10.0%) |
Dec 2019 | - | $12.20 M(+59.5%) |
Sep 2019 | $7.65 M(+172.6%) | $7.65 M(+65.2%) |
Jun 2019 | - | $4.63 M(+14.0%) |
Mar 2019 | - | $4.06 M(+3.2%) |
Dec 2018 | - | $3.94 M(+40.3%) |
Sep 2018 | $2.81 M(-31.2%) | $2.81 M(+29.6%) |
Jun 2018 | - | $2.17 M(+19.6%) |
Mar 2018 | - | $1.81 M(-68.3%) |
Dec 2017 | - | $5.71 M(+40.0%) |
Sep 2017 | $4.08 M(-66.7%) | $4.08 M(+26.1%) |
Jun 2017 | - | $3.23 M(+24.5%) |
Mar 2017 | - | $2.60 M(-29.8%) |
Dec 2016 | - | $3.70 M(-69.8%) |
Sep 2016 | $12.23 M(+143.1%) | $12.23 M(+105.8%) |
Jun 2016 | - | $5.95 M(-21.2%) |
Mar 2016 | - | $7.54 M(+42.6%) |
Dec 2015 | - | $5.29 M(+5.1%) |
Sep 2015 | $5.03 M(+95.1%) | $5.03 M(+3.5%) |
Jun 2015 | - | $4.86 M(-1.5%) |
Mar 2015 | - | $4.94 M(-17.7%) |
Dec 2014 | - | $6.00 M(+132.4%) |
Sep 2014 | $2.58 M(+115.0%) | $2.58 M(+19.5%) |
Jun 2014 | - | $2.16 M(-14.1%) |
Mar 2014 | - | $2.51 M(+326.2%) |
Dec 2013 | - | $589.30 K(-50.9%) |
Sep 2013 | $1.20 M(+36.6%) | $1.20 M(+13.0%) |
Jun 2013 | - | $1.06 M(+21.8%) |
Mar 2013 | - | $871.70 K(+7.7%) |
Dec 2012 | - | $809.50 K(-7.8%) |
Sep 2012 | $878.00 K | $878.00 K(-11.7%) |
Jun 2012 | - | $994.40 K(+24.1%) |
Mar 2012 | - | $801.10 K(+12.2%) |
Date | Annual | Quarterly |
---|---|---|
Dec 2011 | - | $714.10 K(+23.8%) |
Sep 2011 | $576.80 K(-15.4%) | $576.80 K(+15.1%) |
Jun 2011 | - | $501.30 K(+112.5%) |
Mar 2011 | - | $235.90 K(-90.3%) |
Dec 2010 | - | $2.42 M(+255.6%) |
Sep 2010 | $681.60 K(-32.7%) | $681.60 K(-34.0%) |
Jun 2010 | - | $1.03 M(+16.8%) |
Mar 2010 | - | $884.00 K(-0.9%) |
Dec 2009 | - | $891.70 K(-12.0%) |
Sep 2009 | $1.01 M(-24.5%) | $1.01 M(-27.6%) |
Jun 2009 | - | $1.40 M(-30.1%) |
Mar 2009 | - | $2.00 M(+4.7%) |
Dec 2008 | - | $1.91 M(+42.4%) |
Sep 2008 | $1.34 M(-0.5%) | $1.34 M(+23.8%) |
Jun 2008 | - | $1.08 M(-6.6%) |
Mar 2008 | - | $1.16 M(+31.7%) |
Dec 2007 | - | $880.90 K(-34.7%) |
Sep 2007 | $1.35 M(+59.4%) | $1.35 M(-7.2%) |
Jun 2007 | - | $1.45 M(+196.7%) |
Mar 2007 | - | $490.00 K(+25.1%) |
Dec 2006 | - | $391.60 K(-53.7%) |
Sep 2006 | $846.60 K(+79.4%) | $846.60 K(+304.5%) |
Jun 2006 | - | $209.30 K(-87.8%) |
Mar 2006 | - | $1.71 M(+249.3%) |
Dec 2005 | - | $490.90 K(+4.0%) |
Sep 2005 | $471.90 K(-12.7%) | $471.90 K(+37.8%) |
Jun 2005 | - | $342.50 K(-22.9%) |
Mar 2005 | - | $444.50 K(+56.5%) |
Dec 2004 | - | $284.10 K(-47.5%) |
Sep 2004 | $540.70 K(+483.3%) | $540.70 K(+82.2%) |
Jun 2004 | - | $296.80 K(+839.2%) |
Mar 2004 | - | $31.60 K(+112.1%) |
Dec 2003 | - | $14.90 K(-83.9%) |
Sep 2003 | $92.70 K(-64.1%) | $92.70 K(-70.8%) |
Jun 2003 | - | $317.40 K(+6.2%) |
Mar 2003 | - | $298.90 K(+9.4%) |
Dec 2002 | - | $273.30 K(+5.7%) |
Sep 2002 | $258.50 K(+43.6%) | $258.50 K(+4.7%) |
Jun 2002 | - | $246.90 K(+1.5%) |
Mar 2002 | - | $243.20 K(+16.7%) |
Dec 2001 | - | $208.40 K(+15.8%) |
Sep 2001 | $180.00 K(+12.0%) | $180.00 K(+7.6%) |
Jun 2001 | - | $167.30 K(-0.7%) |
Mar 2001 | - | $168.50 K(+8.4%) |
Dec 2000 | - | $155.50 K(-3.2%) |
Sep 2000 | $160.70 K(-5.0%) | $160.70 K(-29.7%) |
Jun 2000 | - | $228.70 K(+9.6%) |
Mar 2000 | - | $208.70 K(+11.9%) |
Dec 1999 | - | $186.50 K |
Sep 1999 | $169.10 K(-88.0%) | - |
Sep 1998 | $1.41 M(-0.7%) | - |
Sep 1997 | $1.42 M | - |
FAQ
- What is Arrowhead Pharmaceuticals annual accounts payable?
- What is the all time high annual accounts payable for Arrowhead Pharmaceuticals?
- What is Arrowhead Pharmaceuticals annual accounts payable year-on-year change?
- What is Arrowhead Pharmaceuticals quarterly accounts payable?
- What is the all time high quarterly accounts payable for Arrowhead Pharmaceuticals?
- What is Arrowhead Pharmaceuticals quarterly accounts payable year-on-year change?
What is Arrowhead Pharmaceuticals annual accounts payable?
The current annual accounts payable of ARWR is $11.39 M
What is the all time high annual accounts payable for Arrowhead Pharmaceuticals?
Arrowhead Pharmaceuticals all-time high annual accounts payable is $35.87 M
What is Arrowhead Pharmaceuticals annual accounts payable year-on-year change?
Over the past year, ARWR annual accounts payable has changed by -$24.48 M (-68.25%)
What is Arrowhead Pharmaceuticals quarterly accounts payable?
The current quarterly accounts payable of ARWR is $11.39 M
What is the all time high quarterly accounts payable for Arrowhead Pharmaceuticals?
Arrowhead Pharmaceuticals all-time high quarterly accounts payable is $35.87 M
What is Arrowhead Pharmaceuticals quarterly accounts payable year-on-year change?
Over the past year, ARWR quarterly accounts payable has changed by +$2.87 M (+33.65%)